Business · 26/10/20261 min read
Opinion/decision on a PIP: Fasenra, Benralizumab, type of decision: PM: Decision on the application for modification of an agreed PIP, therapeutic area: Immunity system disorders;Pneumology-allergology, PIP number: EMA/PE/0000241178
Summary
Opinion/decision on a plan of investigation for paediatrics (PIP): Fasenra, Benralizumab, type of decision: PM: decision on the application for modification of an agreed PIP, therapeutic area: disorders of the immune system;Pneumology-...
Original source language: EMA — Paediatric Investigation PlansOpen original release →